safety-lane.com 07105
NEWARK
http://bit.ly/1DCt06V
New Peanut Allergy Drug Shows Unprecedented Success
Peanut powder immunotherapy helps children and adolescents with severe allergies build tolerance to small amounts of peanut, which could protect many of them from accidental exposure, final results from the phase 3 international PALISADE study (NCT02635776) show.
“In this highly allergic population, treatment with AR101 demonstrated clinical desensitization and an acceptable safety profile in children and adolescents,” said investigator Stephen Tilles, MD, from the University of Washington in Seattle, who is a consulting adviser for Aimmune Therapeutics, which is developing the oral biologic.
He presented findings from the PALISADE study, which were simultaneously published online in the New England Journal of Medicine, here at the American College of Allergy, Asthma & Immunology (ACAAI) 2018 Annual Scientific Meeting.
via Blogger http://bit.ly/2Kku4TT
Recent Comments